SCHEMBL2425632

SCHEMBL2425632

COc1ccc(F)c(Cl)c1[C@@H](C)Oc1c(N)ncc2c(-c3cnn(C4CCNCC4)c3)coc12

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 19/20 0.85
MST1R Q04912 2/20 0.85
CYP3A4 P08684 1/20 0.69
JAK2 O60674 2/20 0.68
JAK1 P23458 2/20 0.68
TYK2 P29597 2/20 0.68
JAK3 P52333 2/20 0.68
MAP4K3 Q8IVH8 2/20 0.58
ALK Q9UM73 2/20 0.58
NUDT1 P36639 1/20 0.58
BMPR1B O00238 1/20 0.58
PLK4 O00444 1/20 0.58
RIOK3 O14730 1/20 0.58
IKBKB O14920 1/20 0.58
CASK O14936 1/20 0.58
AURKA O14965 1/20 0.58
DCLK1 O15075 1/20 0.58
MUSK O15146 1/20 0.58
EPHB6 O15197 1/20 0.58
INPPL1 O15357 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2423926 0.94 MET (0.91) METMST1RCYP3A4JAK2JAK1
SCHEMBL2423846 0.94 MET (0.91) METMST1RCYP3A4JAK2JAK1
SCHEMBL2426856 0.92 MET (1.00) METMST1RCYP3A4JAK2JAK1
SCHEMBL2429915 0.92 MET (1.00) METMST1RCYP3A4JAK2JAK1
SCHEMBL2428419 0.92 MET (1.00) METMST1RCYP3A4JAK2JAK1
Hydrochloric Acid SCHEMBL2422062 0.91 MET (0.99) METMST1RCYP3A4JAK2JAK1
SCHEMBL2428651 0.91 MET (1.00) METMST1RCYP3A4JAK2JAK1
SCHEMBL2420736 0.90 MET (1.00) METMST1RCYP3A4JAK2JAK1
SCHEMBL2424482 0.90 MET (1.00) METMST1RCYP3A4JAK2JAK1
SCHEMBL2422768 0.89 MET (0.89) METMST1RCYP3A4JAK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2265616-B1 FURO-AND THIENO[3,2-C]PYRIDINES OSI PHARM INC (US) 2013-11-20 EP claimed
US-8022206-B2 Furo[3,2-C]pyridines OSI Pharmaceuticals, LLC (US) 2011-09-20 US claimed
US-20090197864-A1 Furo- and Thieno [3,2-c] Pyridines OSI PHARMACEUTICALS, INC. 2009-08-06 US claimed
EP-2265616-B1 FURO-AND THIENO[3,2-C]PYRIDINES OSI PHARM INC (US) 2013-11-20 EP disclosed
US-8022206-B2 Furo[3,2-C]pyridines OSI Pharmaceuticals, LLC (US) 2011-09-20 US disclosed
US-20090197864-A1 Furo- and Thieno [3,2-c] Pyridines OSI PHARMACEUTICALS, INC. 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197864-A1 Furo- and Thieno [3,2-c] Pyridines RET, MET, ERBB2 MET 2/4885MST1R 104/4885CYP3A4 1314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.